TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33097554
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of local anaesthetic
Study: 33097554
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia with or without sedation
Study: 35210352
Drug: Bedtime antihypertensive
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime antihypertensive administration
Study: 35210352
Drug: Morning antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning antihypertensive administration
Study: 32862009
Drug: Anodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal treatment group (tsDCS)
Study: 32862009
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment group
Study: 33865501
Drug: Teprotumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab (10 mg/kg body weight for the first infusion, 20 mg/kg for subsequent infusions, administered every 3 weeks for a total of 8 infusions)
Study: 34275830
Drug: Propofol dosing
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol dosing based on lean body weight (LBW)
Study: 32854693
Drug: Invisalign treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisalign treatment (Control)
Study: 84056285
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral diazepam and supportive care (n = 25)
Study: 84056285
Drug: Further (unblinded)
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further (unblinded) diazepam, 20 mg, every 1 to 2 hr for non-responders (n = 18)
Study: 84056285
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg diazepam doses
Study: 35065063
Drug: Ceftriaxone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (500 mg, intramuscular)
Study: 35065063
Drug: Ertapenem (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1000 mg, intramuscular)
Study: 35065063
Drug: Gentamicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (5 mg/kg, maximum 400 mg, intramuscular)
Study: 35065063
Drug: Fosfomycin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (6 g, oral)
Study: 34711192
Drug: sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 16 mg/kg
Study: 33866311
Drug: Wet cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Study: 33866311
Drug: Sham cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Study: 35412430
Drug: Adjuvant irinotecan-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant irinotecan-based therapy (IFL)
Study: 35412430
Drug: Adjuvant irinotecan-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant irinotecan-based therapy (IFL) in patients with unDCR1 and KRAS-wildtype tumours
Study: 32452549
Drug: Lanadelumab 150
Normalized name: Lanadelumab 150 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 150 mg every 4 weeks
Study: 32452549
Drug: Lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 300 mg every 4 weeks
Study: 39128590
Drug: Lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 300 mg every 2 weeks
Study: 32452549
Drug: Lanadelumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab (all doses)
Study: 35343430
Drug: New sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sodium valproate formulation (epilenil 500-mg coated tablet)
Study: 33098330
Drug: Tablet with
Normalized name: Oral Tablet with Sensor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet with video games (control group)
Study: 34781221
Drug: Traditional Swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Swallowing Therapy (TST) and Neuromuscular Electrical Stimulation (NMES)
Study: 34781221
Drug: Traditional Swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Swallowing Therapy (TST) and Kinesiology Taping (KT)
Study: 34781221
Drug: Traditional Swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Swallowing Therapy (TST), Neuromuscular Electrical Stimulation (NMES), and Kinesiology Taping (KT)
Study: 35392979
Drug: targeted Mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: targeted Mass Drug Administration (tMDA)
Study: 34091276
Drug: Combined CPT
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CPT and Cognitive Symptom Management and Rehabilitation Therapy (SMART-CPT)
Study: 32985396
Drug: Group activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group activity with Paro (robotic seal) for 30 minutes twice a week over 12 weeks
Study: 32621874
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50,000 IU weekly for the first month, followed by 2000 IU daily)
Study: 36484691
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response Cognitive Behavioral Therapy for Chronic Pain (IVR CBT-CP)
Study: 33032770
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg at weeks 0, 4, and 12, and every 8 weeks thereafter
Study: 36184697
Drug: Mepolizumab (3-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (3-24 mg) and Reslizumab (0.1-0.8 mg/kg)
Study: 35345367
Drug: Twice application
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice application of 85% TCA (n=27)
Study: 36181056
Drug: Curcuminoids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids at 1500 mg per day for 3 days before and 2 days after the procedure
Study: 33821899
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg orally daily for 3 years)
Study: 36217848
Drug: COVID-19 vaccination
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccination (2nd dose)
Study: 33421560
Drug: Subcutaneous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tissue disinfection with povidone-iodine solution
Study: 33421560
Drug: Subcutaneous disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous disinfection protocol
Study: 32020438
Drug: SEQ tremelimumab
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEQ tremelimumab 75 mg IV over 1 h followed by durvalumab 1500 mg IV over 1 h q4wks
Study: 32020438
Drug: CON administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON administration of durvalumab and tremelimumab over 1 h
Study: 33009066
Drug: Intrasphincteric BoNTA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrasphincteric BoNTA injection (n = 30)
Study: 33480241
Drug: HCM (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCM (1.5, 3.0 and 6.0 g/kg)
Study: 33480241
Drug: HCM (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCM (6.0 g/kg)
Study: 32981268
Drug: Urtica Dioica
Normalized name: Urtica Dioica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urtica Dioica root extract (UDE) 450 mg day‐1 for 12 weeks
Study: 35565243
Drug: Naldemedine (NAL)
DrugBank: Naldemedine (DB11691)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Naldemedine (NAL) 0.2 mg, once daily
Study: 35565243
Drug: Magnesium Oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium Oxide (MgO) 500 mg, thrice daily
Study: 36454569
Drug: Esketamine infusion
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine infusion (0.3 mg/kg/h)
Study: 33677986
Drug: Tenofovir treatment
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir treatment
Study: 34562067
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200-600 mg of RO7049389
Study: 34562067
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 200-400 mg of RO7049389
Study: 34562067
Drug: Placebo (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple ascending doses)
Study: 33484934
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg daily subcutaneous injection)
Study: 33371157
Drug: Behavioral cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral cognitive therapy technology (sleep hygiene and cognitive therapy)
Study: 32842825
Drug: LSD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 20 µg
Study: 36196515
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using a 940 nm diode laser before dental injection
Study: 35652771
Drug: Posterior Capsule
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior Capsule (PC) approach
Study: 32231293
Drug: FEC14 (fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC14 (fluorouracil, epirubicin and cyclophosphamide administered every 2 weeks)
Study: 32231293
Drug: FEC21 (fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC21 (fluorouracil, epirubicin and cyclophosphamide administered every 3 weeks)
Study: 32231293
Drug: FEC14 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC14 (in hormone receptor-negative tumours)
Study: 32231293
Drug: FEC21 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC21 (in hormone receptor-negative tumours)
Study: 32312333
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder supplementation (400 mg per tablet, 4 tablets daily)
Study: 32312333
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg starch per tablet, 4 tablets daily)
Study: 34922726
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg plus Codeine 30 mg (group APAP/COD)
Study: 34922726
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg (group IBU)
Study: 35562226
Drug: i.v. bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus remimazolam (0.02–0.27 mg kg−1)
Study: 32126267
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (20 mg/m2) with postoperative radiation therapy (total dose 60-66 Gy)
Study: 35926726
Drug: Hexavalent live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent live human-bovine reassortant rotavirus vaccine (HRV)
Study: 32031889
Drug: MK-2206 135
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 135 mg/week
Study: 32031889
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard taxane- and anthracycline-based neoadjuvant therapy)
Study: 36193841
Drug: Baseline insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline insulin level
Study: 33058798
Drug: Cefiderocol 2
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 2 g every 8 hours for 7–14 days
Study: 33058798
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g every 8 hours for 7–14 days
Study: 34376180
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) TXA
Study: 34376180
Drug: TXA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA in a PAMC injection for topical administration
Study: 34376180
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both intravenous and topical administration of TXA
Study: 39326583
Drug: Upadacitinib 45
Normalized name: upadacitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 45 mg
Study: 33646842
Drug: Slow continuous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow continuous infusion of hypertonic saline
Study: 36078774
Drug: Training (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training (16 weeks of combined training including walking/running at 63% of V˙O2max, three times per week, and strength training, consisting of one set of fifteen repetitions at moderate intensity, twice per week)
Study: 33347829
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus chemotherapy (carboplatin and pemetrexed)
Study: 36340667
Drug: Intrauterine injection
Normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine injection of autologous PRP
Study: 36340667
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of fetal transfer without intrauterine PRP injection
Study: 35410938
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXY) spray (24 IU)
Study: 35410938
Drug: Placebo (PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLC) spray plus oral naltrexone (NTX) (50 mg)
Study: 35329972
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with a new nutritional product developed by the Grand Fontaine Laboratories
Study: 33728044
Drug: Medicines and
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicines and Alcohol Consultation (MAC) intervention
Study: 33026570
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone (Control)
Study: 35064716
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg for 7 days
Study: 35064716
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg single dose
Study: 35448154
Drug: Intensive arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive arm (8 phone counseling sessions + 8 weeks of nicotine replacement therapy)
Study: 35448154
Drug: Minimal arm
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal arm (3 sessions + 2 weeks of nicotine replacement therapy)
Study: 34052928
Drug: Infrared laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Study: 34052928
Drug: Red laser
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Study: 35821731
Drug: Rapid Treatment
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Treatment
Study: 35212136
Drug: Intralesional Purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Purified Protein Derivative (PPD) 10 IU (0.1 ml)
Study: 32356170
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injection (SCI)
Study: 32356170
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injection plus suprascapular nerve block (SSNB)
Study: 33270009
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement treatment in England
Study: 33170261
Drug: Sodium Benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Benzoate (500 mg twice daily)
Study: 34468080
Drug: Filgotinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib (200 mg once daily for 11 days)
Study: 34501669
Drug: Standard paper–pencil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard paper–pencil treatment
Study: 35293973
Drug: Early supplemental
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early supplemental parenteral nutrition (E‐SPN) starting on day 3 after surgery
Study: 35293973
Drug: Late supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late supplemental parenteral nutrition (L‐SPN) starting on day 8 after surgery
Study: 32113839
Drug: GCs +
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCs + LEF (20 mg/day)
Study: 32113839
Drug: GCs monotherapy
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCs monotherapy
Study: 36232122
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with intramuscular injections of pIRES/VEGF165/HGF plasmids and 1 month of ANG-1 plasmids
Study: 35244019
Drug: Hysteroscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic treatment of Asherman syndrome
Study: 35078490
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care chemotherapy (SoC-CT) without SBRT
Study: 33327737
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice/day
Study: 33952741
Drug: Grains of
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grains of Paradise (GP) extract (40 mg/d)
Study: 32541510
Drug: Yuanhu Zhitong
Normalized name: METHYL SALICYLATE 13 g / MENTHOL 9 g / CAMPHOR (SYNTHETIC) 11 g TOPICAL PATCH [KGS Zhitong Gao Medicated Plaster Extra Strength]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuanhu Zhitong dropping pills
Study: 32541510
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium sustained-release capsule
Study: 616081112
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 5mg/ml
Study: 616081112
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac 9mg/ml
Study: 32451827
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (15 mg/kg/dose)
Study: 32451827
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg/dose)
Study: 35758374
Drug: High-dose Resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Resveratrol (500 mg/d)
Study: 35758374
Drug: Middle-dose Resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose Resveratrol (250 mg/d)
Study: 35758374
Drug: Low-dose Resveratrol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Resveratrol (125 mg/d)
Study: 34264701
Drug: TranS‐C +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TranS‐C + UC (n = 61; 8 individual weekly sessions)
Study: 34974435
Drug: Neurofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback treatment reinforcing reductions in theta activity
Study: 35737076
Drug: Active Control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Control Treatment (AC)
Study: 32250021
Drug: Daprodustat 2-mg
Normalized name: daprodustat 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 2-mg tablet
Study: 32250021
Drug: Daprodustat 4-mg
Normalized name: daprodustat 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 4-mg tablet
Study: 36342737
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide system during MFU-V treatment
Study: 33135429
Drug: Lacidipine (4–6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4–6 mg/day)
Study: 33135429
Drug: Amlodipine (5–7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5–7.5 mg/day)
Study: 35121270
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for antenatal depression
Study: 33161581
Drug: Traditional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional training videos on CBCT and implant planning
Study: 34635140
Drug: Wearable +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable + Symptom Data Algo (Ava bracelet data + Daily Symptom Diary data)
Study: 34635140
Drug: Symptom Only
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom Only Algo (Daily Symptom Diary data alone)
Study: 70655980
Drug: Everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVR) 3-8 ng/mL
Study: 70655980
Drug: Everolimus (EVR)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVR) 6-12 ng/mL
Study: 70655980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Mycophenolate sodium 1.44 g/day with standard dose CsA)
Study: 33275070
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use in last 4 weeks
Study: 32631427
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy (ERYT)